Amgen Inc. $AMGN Shares Sold by Jennison Associates LLC

Jennison Associates LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,980 shares of the medical research company’s stock after selling 2,484 shares during the period. Jennison Associates LLC’s holdings in Amgen were worth $45,733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Amgen by 1.6% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 7,969 shares of the medical research company’s stock worth $2,804,000 after buying an additional 127 shares during the last quarter. German American Bancorp Inc. raised its stake in Amgen by 142.9% during the 1st quarter. German American Bancorp Inc. now owns 4,304 shares of the medical research company’s stock valued at $1,514,000 after acquiring an additional 2,532 shares during the last quarter. Ranch Capital Advisors Inc. raised its stake in Amgen by 5.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 10,928 shares of the medical research company’s stock valued at $3,845,000 after acquiring an additional 521 shares during the last quarter. Zhang Financial LLC lifted its position in Amgen by 9.6% during the 1st quarter. Zhang Financial LLC now owns 21,120 shares of the medical research company’s stock worth $7,431,000 after acquiring an additional 1,847 shares during the period. Finally, Atlas Wealth LLC grew its stake in shares of Amgen by 11,152.0% in the 1st quarter. Atlas Wealth LLC now owns 72,463 shares of the medical research company’s stock valued at $25,496,000 after purchasing an additional 71,819 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.6%

Shares of AMGN opened at $364.17 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm’s 50-day moving average is $348.38 and its two-hundred day moving average is $350.78. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The firm has a market capitalization of $196.55 billion, a P/E ratio of 25.34, a PEG ratio of 3.71 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts predict that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Truist Financial upped their price target on Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Guggenheim raised their target price on shares of Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Weiss Ratings downgraded shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $356.62.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.